San Diego-based mostly Viking Therapeutics marked alone as a serious competitor while in the weight loss drug market place in February immediately after revealing promising data from a mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when presented as being a weekly injection As well as